News By Tag
News By Place
AIM Coalition Meeting Highlights Latest Developments in Sarcopenia Research
Experts from the FDA and Science, Industry and Advocacy Groups Discuss Strategies to Advance Treatment for Condition
According to Dan Perry, the chair of the AIM Coalition, the meeting represented an opportunity to educate FDA colleagues about the growing consensus among clinicians on the common measures that will most accurately reveal outcomes that yield effective therapies to treat sarcopenia and counter functional decline.
“At present, the FDA does not have an official policy on sarcopenia nor has it approved any drugs for the treatment of this condition,” he said. “The AIM Coalition has dedicated its efforts to changing this through collaboration, education and creating a common consensus on appropriate therapy development strategies. Our meeting with the FDA is a first important step in demonstrating we are on the right path to accomplishing our goal.”
Among the experts who presented at the meeting were:
● Maria Vassileva, Ph.D., senior scientific program manager, FNIH Biomarkers Consortium
● Jack M. Guralnik, M.D., Ph.D., M.P.H., professor, Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine
● Donald Patrick, Ph.D., professor, Health Services, University of Washington
The AIM Coalition will communicate more information from the meeting on its website in the coming weeks. Please visit aginginmotion.org for more updates. You can also follow its Twitter feed: @aginginmotion
About the AIM Coalition
The Aging in Motion (AIM) Coalition is a diverse group of patient, caregiver, health and aging groups working together to press for greater levels of research and innovation to develop treatments in the area of sarcopenia and age-related functional decline. Initiated by the Alliance for Aging Research, the AIM Coalition members are leading ongoing interactions with clinicians, regulators and policy influencers to overcome obstacles that impede the development and evaluation of promising treatments for sarcopenia and associated functional decline in people as they age. AIM members represent patients, providers, caregivers, consumers, aging Americans, researchers, employers and the health care industry.
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Sarcopenia is thought to play a major role in the increased frailty and functional impairment that comes with age. Possible effects of sarcopenia include decreased muscle strength, problems with mobility, frailty, weak bones (osteoporosis)